Our safe and non-invasive test was validated by a 5-year NIH-sponsored study. The test predicted patients' risk of developing mild cognitive impairment and Alzheimer's disease.
Neurotrack has the potential to identify Alzheimer’s patients years before symptoms appear, giving pharmaceutical companies better tools to recruit patients for clinical trials.
Neurotrack is developing a behavioral biomarker to help physicians make an earlier and more accurate assessment of a patient's risk of developing Alzheimer's disease.
Physicians will be able to administer our computer-based test in their offices or via the web in five minutes. The test is non-invasive, easy to take, and is not language-specific.
Early Diagnosis is Essential
Today, Alzheimer’s is diagnosed only when symptoms become apparent, after the disease has destroyed critical memory centers over the course of many years. Early diagnosis will facilitate drug development, creating the potential to accelerate treatment options.